 HAYWARD, Calif., April 27, 2021 PRNewswire -- Benitec Biopharma Inc. NASDAQ: BNTC Benitec or the Company, a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ddRNAi platform, today announced that it has entered into an underwriting agreement with H.C. 